SEATTLE (March 3, 2025)—Perkins Coie is pleased to have advised Pacira BioSciences, Inc., an innovative biopharmaceutical company that develops non-opioid pain therapies, in its acquisition of GQ Bio Therapeutics GmbH, a privately held biopharmaceutical company with a novel, high-capacity, local-delivery platform that makes genetic medicines more efficient and enables the use of large and multiple gene constructs. For more information, please see Pacira’s press release here.
Pacira BioSciences, Inc. is committed to reducing the need for opioids and enhancing patient outcomes through cutting-edge technologies and therapies that address a wide range of pain management needs. This transaction builds upon Pacira’s previous investments in GQ Bio, as well as the two companies’ partnership for the development of a commercially scalable manufacturing process for PCRX-201 (enekinragene inzadenovec) and other products utilizing GQ Bio’s high-capacity adenovirus, or HCAd, gene therapy vector platform.
The Perkins Coie Mergers and Acquisitions advisory team was led by partners Jason Day and Arian Galavis, and included counsel Matt Klomparens, and associate Hannah Lanham.
